Venlafaxine Besylate is a drug owned by Almatica Pharma Llc. It is protected by 2 US drug patents filed in 2022. Out of these, 1 drug patents are active and 1 has expired. Based on its patents and exclusivities, its generic launch date is estimated to be May 16, 2028. Details of Venlafaxine Besylate's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US6717015 | Venlafaxine besylate |
Mar, 2023
(1 year, 8 months ago) |
Expired
|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7776358 | Extended release venlafaxine besylate tablets |
May, 2028
(3 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Venlafaxine Besylate's patents.
Latest Legal Activities on Venlafaxine Besylate's Patents
Given below is the list of recent legal activities going on the following patents of Venlafaxine Besylate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 02 Feb, 2022 | US7776358 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 03 Aug, 2018 | US7776358 |
| 7.5 yr surcharge - late pmt w/in 6 mo, Large Entity | 03 Aug, 2018 | US7776358 |
| Mail O.P. Petition Decision | 02 Aug, 2018 | US7776358 |
| Email Notification Critical | 02 Aug, 2018 | US7776358 |
| Mail-Petition Decision - Accept Late Payment of Maintenance Fees - Granted Critical | 31 Jul, 2018 | US7776358 |
| Surcharge, Petition to Accept Pymt After Exp, Unintentional Critical | 30 Jul, 2018 | US7776358 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 30 Jul, 2018 | US7776358 |
| O.P. Petition Decision | 30 Jul, 2018 | US7776358 |
| Petition Decision - Accept Late Payment of Maintenance Fees - Granted Critical | 30 Jul, 2018 | US7776358 |
While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Venlafaxine Besylate and ongoing litigations to help you estimate the early arrival of Venlafaxine Besylate generic.
Venlafaxine Besylate's Litigations
Venlafaxine Besylate been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Dec 31, 2008, against patent number US7776358. The petitioner , challenged the validity of this patent, with Joan Cucala Escoi et al as the respondent. Click below to track the latest information on how companies are challenging Venlafaxine Besylate's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US7776358 | December, 2008 |
Decision
(13 Feb, 2010) | Joan Cucala Escoi et al | |
US patents provide insights into the exclusivity only within the United States, but Venlafaxine Besylate is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Venlafaxine Besylate's family patents as well as insights into ongoing legal events on those patents.
Venlafaxine Besylate's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Venlafaxine Besylate's generic launch date based on the expiry of its last outstanding patent is estimated to be May 16, 2028 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Venlafaxine Besylate Generics:
There are no approved generic versions for Venlafaxine Besylate as of now.
Alternative Brands for Venlafaxine Besylate
Venlafaxine Besylate which is used for treating depression and generalized anxiety disorder., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Upjohn |
| |||
About Venlafaxine Besylate
Venlafaxine Besylate is a drug owned by Almatica Pharma Llc. It is used for treating depression and generalized anxiety disorder. Venlafaxine Besylate uses Venlafaxine Besylate as an active ingredient. Venlafaxine Besylate was launched by Almatica in 2022.
Approval Date:
Venlafaxine Besylate was approved by FDA for market use on 29 June, 2022.
Active Ingredient:
Venlafaxine Besylate uses Venlafaxine Besylate as the active ingredient. Check out other Drugs and Companies using Venlafaxine Besylate ingredient
Treatment:
Venlafaxine Besylate is used for treating depression and generalized anxiety disorder.
Dosage:
Venlafaxine Besylate is available in tablet, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 112.5MG BASE | TABLET, EXTENDED RELEASE | Prescription | ORAL |